15 February 2015Subscribe to our news feed

Testosterone and Weight Loss - the Evidence

Testosterone and Weight Loss - the Evidence

Lowered testosterone in male obesity: mechanisms, morbidity and management. Ng Tang Fui M, Dupuis P, Grossmann M. Asian journal of andrology. 2014;16(2):223-231.

Testosterone and weight loss: the evidence. Traish AM. Current opinion in endocrinology, diabetes, and obesity. 2014;21(5):313-322.

Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Saad F, Aversa A, Isidori AM, Gooren LJ. Current diabetes reviews. 2012;8(2):131-143.

The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Saad F, Gooren LJ. Journal of obesity. 2011;2011.

It is well documented that obesity may cause hypogonadism, and that hypogonadism may cause obesity.1-4 This has generated debate about what condition comes first; obesity or hypogonadism? And what should be the first point of intervention?

In this editorial we summarize data from several reviews on the association of obesity and hypogonadism1-4, and make the case that obesity and hypogonadism create a self-perpetuating vicious circle. Once a vicious circle has been established, it doesn’t matter where one intervenes; one can either treat the obese condition or treat hypogonadism first. The critical issue is to break the vicious circle as soon as possible before irreversible health damage arises.

Nevertheless, as we will explain here, treating hypogonadism first may prove more effective in that it to a large extent “automatically” takes care of the excess body fat and metabolic derangements, and also confers psychological benefits that will help obese men become more physically active. Thereby, restoring testosterone levels in hypogonadal obese men will relatively quickly break the self-perpetuating vicious circle, and transform it into a “health promoting circle.”

Key Points

  • Non-obese men who become obese experience a decline of testosterone levels comparable to that of 10 years of aging.
  • Testosterone deficiency and obesity each contribute independently to a self-perpetuating vicious cycle. Long-term testosterone replacement therapy in men with hypogonadism improves body composition, metabolic syndrome components and quality of life, and thereby can help break the vicious cycle.
  • Treatment of hypogonadism with long-term testosterone replacement therapy, with or without lifestyle modifications, effectively treats obesity by correcting testosterone deficiency; one physiological root cause of obesity.
  • In contrast to the U-shaped curve for weight loss seen with traditional obesity treatments, which are characterized by weight loss and weight regain, treatment with testosterone replacement therapy results in a continuous reduction in obesity parameters (waist circumference, weight and BMI) for >5 years, or until metabolic abnormalities return to healthy ranges.
  • The significant effectiveness of testosterone replacement therapy in combating obesity in hypogonadal men remains largely unknown to doctors. Educational efforts are therefore critical to bring research findings into clinical practice in order to improve patient care and health outcomes.

What is known

Obesity, classified by the American Medical Association in 2013 as a disease, is an epidemic that is rapidly spreading globally. Obesity is the most common preventable disease and the most common modifiable risk factor for several chronic diseases5,6; it is notable that obesity is an independent risk factor for cardiovascular disease7,8 and type 2 diabetes9,10, as well as an independent cause of increased morbidity and mortality.5 With the contemporary pervasive unhealthy food habits and sedentary lifestyles, it is anticipated that the prevalence of obesity and its health consequences will continue to rise.11 Over the last decade, an escalation in diabetes incidence has paralleled the rapid increase in obesity prevalence, constituting a global health crisis.12 The concurrent occurrence of obesity and diabetes in the same individual, known as “diabesity” is also rising in prevalence at a fast pace.13,14

A comprehensive program of lifestyle modification can produce a 7% to 10% reduction of body weight and clinically meaningful improvements in several cardiovascular risk factors, including the prevention of type 2 diabetes.15 However, long-term maintenance of lifestyle induced weight loss is notoriously difficult and fails for the large majority.16 In turn, anti-obesity drugs have limited efficacy and adverse side effects that limit their use.5,17

Therefore, new interventions are urgently needed to combat this alarming preventable threat to society. A new line of reasoning has suggested that it is time to test hormonal theories about why people get fat.18 Testosterone is a promising candidate.

What these reviews adds

Multiple lines of evidence, from experimental to observational studies, and randomized controlled trials of both testosterone replacement therapy and testosterone deprivation, show the critical role of testosterone in regulation of body fat metabolism and body composition.1-4

Obesity as a cause of hypogonadism - Evidence that obesity leads to low testosterone

Multiple observational studies in community-dwelling men suggest that obesity leads to decreased testosterone. Cross-sectional analyses show that obese men have lower testosterone levels than age-matched non-obese men.19,20 In the prospective Massachusetts Male Aging Study (MMAS), non-obese men who became obese had a decline of testosterone levels comparable to that of 10 years of aging.21 Another prospective study confirmed that weight gain results in a proportional decrease in testosterone levels at follow-up.22 Obesity, metabolic syndrome, diabetes and dyslipidaemia have been identified as risk factors of incident hypogonadism.23

Hypogonadism as a cause of obesity - Evidence that low testosterone leads to obesity

There is also ample evidence, both from experimental and human studies, to suggest the reverse. Lower baseline testosterone levels independently predict an increase in intra-abdominal fat after 7.5 years of follow-up.24 Experimental induction of hypogonadism in healthy men aged 20-50 years, significantly increases body fat mass within 16 weeks, indicating that severe testosterone deficiency rapidly causes body fat gain.25 Moreover, men with prostate cancer receiving androgen deprivation therapy show marked increases in total body fat mass and abdominal visceral fat within 6 months.26

Further proof of the causal role of testosterone in the pathogenesis of obesity comes from a growing number of studies showing that testosterone replacement therapy significantly reduces several markers of obesity, (including weight, waist circumference and BMI)27-31, total body fat mass32-37 and intra-abdominal fat mass.37-40

While testosterone is most known for its effect on libido and sexual function, it plays a key role in fat, carbohydrate and protein metabolism as well.37,41-45 The exact mechanisms by which testosterone acts on pathways to control metabolism are not fully clear. Nevertheless, data from animal, cell and clinical studies show that testosterone at the molecular level controls the expression of important regulatory proteins involved in energy and substrate metabolism.41 The cumulative effects of testosterone on these biochemical pathways would account for the overall benefits seen with testosterone replacement therapy on fat loss and body composition.

Low testosterone and obesity: a self-perpetuating vicious cycle

When taking into consideration both sides of the testosterone – obesity link, it becomes clear that a bidirectional relationship exists between testosterone and obesity, initiating and reinforcing a self-perpetuating cycle (figure 1).

Figure 1: Bidirectional relationship between low testosterone and obesity, initiating and reinforcing a self-perpetuating cycle.
Figure 1: Bidirectional relationship between low testosterone and obesity, initiating and reinforcing a self-perpetuating cycle.

On the one hand, increasing body fat suppresses the HPT (hypothalamic-pituitary-gonadal) axis by multiple mechanisms; via increased insulin resistance, metabolic syndrome and diabetes46,47, and elevation in estradiol and cortisol levels.48,49 Because of this, it has been suggested that obesity-induced hypogonadism should be regarded as a distinct subtype of hypogonadism.50

On the other hand, low testosterone promotes accumulation of total and visceral fat mass, thereby inducing and/or exacerbating the gonadotropin inhibition, which will further reduce testosterone levels.46,48,49 A recent placebo-controlled study investigated the effects of testosterone replacement therapy on obesity, HbA1c, hypertension and dyslipidemia in hypogonadal diabetic patients.51 It was found that testosterone replacement therapy did break the metabolic vicious circle by raising testosterone levels, and it was concluded that re-instituting physiological levels of testosterone has an important role in reducing the prevalence of diabetic complications.51

Psychological effects – Adherence to lifestyle changes

Testosterone replacement therapy as an obesity treatment confers additional benefits in that it consistently improves mood and feelings of energy, and reduces fatigue52-56; this in turn may bolster motivation to adhere to diet and exercise regimens designed to combat obesity.2 This has been demonstrated in studies that added testosterone or placebo to diet and exercise recommendations or structured programs.57,58

Because testosterone improves mitochondrial function, hypogonadism may cause mitochondrial dysfunction and thereby give rise to fatigue, which in turn negatively impacts the sense of energy and vitality, and the “pick-up-and-go” mentality.59 Therefore, testosterone replacement therapy, by addressing a root cause of obesity, can help obese men adhere to exercise programs and thereby not only break the vicious circle, but also initiate a health promoting circle.

Remarks

It is of utmost interest that in contrast to the U-shaped curve for weight loss seen with traditional obesity treatments, which are characterized by weight loss and weight regain, treatment with testosterone replacement therapy results in a continuous reduction in obesity parameters (waist circumference, weight and BMI) for >5 years, or until metabolic abnormalities return to healthy ranges.27-31

Testosterone replacement therapy has been proposed to be a new potential obesity treatment modality in hypogonadal men with excessive body fat mass and metabolic derangements.2 It should be underscored that the contribution of testosterone replacement therapy to combating obesity remains largely unknown to medical professionals.2 It is therefore important to highlight the promising research on the anti-obesity effects of testosterone replacement therapy and help implement its research findings into clinical practice, for the benefit of a growing population of suffering hypogonadal obese men.

top of page

References

1. Ng Tang Fui M, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian journal of andrology. 2014;16(2):223-231.
2. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current diabetes reviews. 2012;8(2):131-143.
3. Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Journal of obesity. 2011;2011.
4. Traish AM. Testosterone and weight loss: the evidence. Current opinion in endocrinology, diabetes, and obesity. 2014;21(5):313-322.
5. Patham B, Mukherjee D, San Juan ZT. Contemporary review of drugs used to treat obesity. Cardiovascular & hematological agents in medicinal chemistry. 2013;11(4):272-280.
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875-880.
7. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977.
8. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.
9. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961-969.
10. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35(4):717-722.
11. Bhurosy T, Jeewon R. Overweight and Obesity Epidemic in Developing Countries: A Problem with Diet, Physical Activity, or Socioeconomic Status? TheScientificWorldJournal. 2014;2014:964236.
12. Colagiuri S. Diabesity: therapeutic options. Diabetes, obesity & metabolism. 2010;12(6):463-473.
13. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol. Dial. Transplant. 2011;26(1):28-35.
14. Kral JG. Diabesity: palliating, curing or preventing the dysmetabolic diathesis. Maturitas. 2014;77(3):243-248.
15. Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation. 2012;125(9):1157-1170.
16. Wing RR, Phelan S. Long-term weight loss maintenance. Am. J. Clin. Nutr. 2005;82(1 Suppl):222S-225S.
17. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nature reviews. Endocrinology. 2013;9(8):467-478.
18. Taubes G. Treat obesity as physiology, not physics. Nature. 2012;492(7428):155.
19. Yeap BB, Chubb SA, Hyde Z, et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. Eur. J. Endocrinol. 2009;161(4):591-598.
20. Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J. Clin. Endocrinol. Metab. 2012;97(5):1508-1516.
21. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J. Clin. Endocrinol. Metab. 2007;92(2):549-555.
22. Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur. J. Endocrinol. 2013;168(3):445-455.
23. Haring R, Ittermann T, Volzke H, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. The aging male : the official journal of the International Society for the Study of the Aging Male. 2010;13(4):247-257.
24. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int. J. Obes. Relat. Metab. Disord. 2000;24(4):485-491.
25. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 2013;369(11):1011-1022.
26. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin. Endocrinol. (Oxf). 2011;74(3):377-383.
27. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract. 2014;8(4):e339-349.
28. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International journal of endocrinology. 2014;2014:683515.
29. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013;21(10):1975-1981.
30. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 2014;68(3):314-329.
31. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical obesity. 2013;3(3-4):73-83.
32. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J. Clin. Endocrinol. Metab. 2005;90(3):1502-1510.
33. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 1999;84(8):2647-2653.
34. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A. Biol. Sci. Med. Sci. 2001;56(5):M266-272.
35. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A. Biol. Sci. Med. Sci. 2003;58(7):618-625.
36. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000;85(8):2839-2853.
37. Sattler F, He J, Chukwuneke J, et al. Testosterone Supplementation Improves Carbohydrate and Lipid Metabolism in Some Older Men with Abdominal Obesity. Journal of gerontology & geriatric research. 2014;3(3):1000159.
38. Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes. Res. 1993;1(4):245-251.
39. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. 1992;16(12):991-997.
40. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J. Clin. Endocrinol. Metab. 2008;93(1):139-146.
41. Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J. Endocrinol. 2013;217(3):R25-45.
42. Frederiksen L, Hojlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr). 2012;34(1):145-156.
43. Petersson SJ, Christensen LL, Kristensen JM, Kruse R, Andersen M, Hojlund K. Effect of testosterone on markers of mitochondrial oxidative phosphorylation and lipid metabolism in muscle of aging men with subnormal bioavailable testosterone. Eur. J. Endocrinol. 2014;171(1):77-88.
44. Griggs RC, Kingston W, Jozefowicz RF, Herr BE, Forbes G, Halliday D. Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol (1985). 1989;66(1):498-503.
45. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J. Clin. Endocrinol. Metab. 1996;81(10):3469-3475.
46. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J. Clin. Endocrinol. Metab. 2011;96(8):2341-2353.
47. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J. Clin. Endocrinol. Metab. 2005;90(5):2636-2641.
48. Mah PM, Wittert GA. Obesity and testicular function. Mol. Cell. Endocrinol. 2010;316(2):180-186.
49. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Med. Hypotheses. 1999;52(1):49-51.
50. Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin. Endocrinol. (Oxf). 2013;78(3):330-337.
51. Janjgava S, Zerekidze T, Uchava L, Giorgadze E, Asatiani K. Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency. Eur. J. Med. Res. 2014;19(1):56.
52. Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann. Clin. Psychiatry. 2014;26(1):19-32.
53. Spitzer M, Basaria S, Travison TG, Davda MN, DeRogatis L, Bhasin S. The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology. 2013;1(3):475-482.
54. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J. Clin. Endocrinol. Metab. 1996;81(10):3578-3583.
55. Jockenhovel F, Minnemann T, Schubert M, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur. J. Endocrinol. 2009;160(5):815-819.
56. Jockenhovel F, Minnemann T, Schubert M, et al. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. The aging male : the official journal of the International Society for the Study of the Aging Male. 2009;12(4):113-118.
57. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin. Endocrinol. (Oxf). 2010;73(5):602-612.
58. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J. Androl. 2009;30(6):726-733.
59. Traish A, Abdallah B, Yu G. Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease. . Horm Mol Biol Clin Invest 2011;8:431–444.
top of page
Last updated: 2017
G.GM.MH.04.2015.0334